For the treatment of dyslipidaemia associated with atherosclerotic arterial disease with risk of myocardial infarction, stroke or peripheral vascular disease.
Rosuvastatin is an inhibitor of HMG-CoA reductase, an enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. Aspirin blocking the platelet cyclooxygenase by acetylation, it inhibits thromboxane A2 synthesis, a physiological activating substance released by the platelets.
Once daily, orally after food any time of the day.
Hypersensitivity to the active substance(s) or to any of the excipients. Asthma, rhinitis, and nasal polyps, pregnant and nursing women. Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels, Nasal polyps associated with asthma (high risk of severe sensitivity reactions).
Skeletal muscle effects (e.g., myopathy and rhabdomyolysis). Monitor liver enzymes before and during treatment. Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including Rosuvastatin. Aspirin increases the risk of bleeding. Increased risk of bleeding., Gastric mucosal irritation and bleeding.
There are no adequate and well-controlled studies in human pregnancy, lactation and children.
Following drug interact with Rosuvastatin caution to be taken with Cyclosporine, Gemfibrozil, Lopinavir/Ritonavir or atazanavir/ritonavir, Coumarin anticoagulants and fibrates. Aspirin administered with Anticoagulant and anti-platelets causes increased risk of bleeding.
The most commonly reported adverse events of rosuvastatin are headache, myalgia, abdominal pain, asthenia, nausea. gastrointestinal dyspepsia, hepatic enzyme elevation, hepatitis, Reye’s Syndrome.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS